首页 | 本学科首页   官方微博 | 高级检索  
     


Management Options for Irritable Bowel Syndrome
Authors:Michael Camilleri
Affiliation:Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.) Program and Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
Abstract:Irritable bowel syndrome (IBS) is associated with diverse pathophysiologic mechanisms. These mechanisms include increased abnormal colonic motility or transit, intestinal or colorectal sensation, increased colonic bile acid concentration, and superficial colonic mucosal inflammation, as well as epithelial barrier dysfunction, neurohormonal up-regulation, and activation of secretory processes in the epithelial layer. Novel approaches to treatment include lifestyle modification, changes in diet, probiotics, and pharmacotherapy directed to the motility, sensation, and intraluminal milieu of patients with IBS. Despite recent advances, there is a need for development of new treatments to relieve pain in IBS without deleterious central or other adverse effects.
Keywords:CFU  colony-forming units  FDA  Food and Drug Administration  FODMAPs  fructose, oligosaccharides, disaccharides, monosaccharides, and polyols  GFD  gluten-free diet  5-HT  5-hydroxytryptamine (serotonin)  IBS  irritable bowel syndrome  IBS-C  constipation-predominant IBS  IBS-D  diarrhea-predominant IBS  IBS-SSS  IBS symptom severity score  NNT  number needed to treat  RCT  randomized controlled trial  SNRI  serotonin-norepinephrine reuptake inhibitor  SSRI  selective serotonin reuptake inhibitor  TCA  tricyclic antidepressant  TRP  transient receptor potential
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号